Indian Lobby Groups Laud Global Efforts To Eliminate NTDs But Call For Stronger Grassroots Delivery Mechanism
This article was originally published in PharmAsia News
Executive Summary
India lobby groups question whether global efforts to eliminate neglected tropical diseases will provide concrete local solutions, noting that drugs are just a part of the problem.
You may also be interested in...
DNDi Mulls Expansion Of India Site; Set To Team With More Pharma On The Heels Of Sanofi Deal - BIO Conference
WASHINGTON - Six years after establishing its India office, Geneva-based Drugs for Neglected Diseases Initiative (DNDi) is planning to expand its presence to cater to the drug development needs of the Indian population as well as neighboring countries like Bangladesh and Sri Lanka
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.